The European Commission has approved Merck’s Keytruda as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 (combined positive score [CPS] ≥1). The drug was approved Nov. 20.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
